Keros Therapeutics
Keros Therapeutics reported revenue of $244 million in fiscal 2025. Its operating margin was 27.7%. Free cash flow was $106 million. It paid out $375 million in dividends and buybacks, 354% of free cash flow. The diluted share count rose 1.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Keros Therapeutics does
Keros Therapeutics is a clinical-stage biopharmaceutical company, which means it is testing medicines in people and has none approved for sale. It develops protein-based drugs for disorders linked to the TGF-beta family of proteins, which help control how muscle, bone, fat, heart tissue and blood grow and repair.
Its most advanced candidate is elritercept, aimed at low blood cell counts such as anemia and low platelets in patients with myelodysplastic syndromes and with myelofibrosis. In December 2024 it signed an exclusive license with Takeda to develop, make and sell elritercept worldwide outside mainland China, Hong Kong and Macau. The agreement took effect on January 16, 2025.
Its lead candidate, rinvatercept, is a drug being developed for neuromuscular diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. A Phase 1 trial in healthy volunteers has reported initial results, and the company expects to start a Phase 2 trial in Duchenne patients.
Its biggest risks, as it describes them
- It has lost money every year since it began and expects more losses.
- It needs substantial additional funding, which could dilute owners or restrict it.
- All its product candidates are in development, and its clinical trials may fail to show they are safe and effective.
- Early trial results may not predict later results, and early data it reports may change.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 230 | 279 | 331 | 560 | 287 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −14,093.2x | −114,790.0x | — | — | — |
| Current ratio | 21.2x | 17.3x | 14.2x | 21.4x | 15.4x |
| Quick ratio | 21.2x | 17.3x | 14.2x | 21.4x | 15.4x |
Cash flow
Projections
Project Keros Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Keros Therapeutics says to expect
- Cash runway: cash and cash equivalents
Based on current operating assumptions, Keros expects that its cash and cash equivalents as of September 30, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the second half of 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $75,770 of Keros Therapeutics shares on the open market, and 9 insiders sold $506,996, $79,714 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Anne PrenerDirector | Sold plan | 575 | $10.83 | $6,230 | Form 4 |
| Nov 17, 2026 | Charles W. NewtonDirector | Sold plan | 551 | $10.85 | $5,981 | Form 4 |
| Aug 18, 2026 | Esther ChoChief Legal Officer | Sold | 4,485 | $10.29 | $46,151 | Form 4 |
| Aug 18, 2026 | Lorena Raquel LernerChief Scientific Officer | Sold | 3,568 | $10.29 | $36,715 | Form 4 |
| Aug 18, 2026 | Annita TaniniCorp. Controller & VP, Finance | Sold | 1,224 | $10.29 | $12,595 | Form 4 |
| Aug 18, 2026 | Charles W. NewtonDirector | Sold plan | 551 | $10.30 | $5,675 | Form 4 |
| Aug 17, 2026 | Jean Jacques BienaimeDirector | Bought plan | 1,000 | $10.27 | $10,270 | Form 4 |
| Jul 15, 2026 | Jean Jacques BienaimeDirector | Bought plan | 1,000 | $10.61 | $10,610 | Form 4 |
| Jun 15, 2026 | Jean Jacques BienaimeDirector | Bought plan | 1,000 | $10.19 | $10,190 | Form 4 |
| Jun 11, 2026 | Charles W. NewtonDirector | Sold plan | 550 | $10.04 | $5,522 | Form 4 |
| Jun 4, 2026 | Nima FarzanDirector | Sold plan | 2,625 | $10.73 | $28,166 | Form 4 |
| Jun 4, 2026 | Alpna SethDirector | Sold plan | 2,625 | $10.72 | $28,140 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 8.50 | 14.21 | 11.55 |
| Accruals ratio | −8.4% | −5.4% | −4.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Keros Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics | FY25 | — | 27.7% | 43.5% | — | — | — | |
| Arcus Biosciences | FY25 | −4.3% | −156.3% | −195.9% | — | — | 0 | Compare |
| Arvinas | FY25 | −0.3% | −45.1% | −105.0% | — | — | 5 | Compare |
| Iovance Biotherapeutics | FY25 | 60.6% | −153.1% | −127.6% | — | — | — | Compare |
| Ligand Pharmaceuticals | FY25 | 60.4% | 15.3% | 18.2% | 4.9% | −3.8x | 5 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 10 | 0 | 20 | 0 | 0 | 0 | 244 |
| Revenue growth | — | −100.0% | — | −100.0% | — | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 17 | 34 | 55 | 87 | 135 | 174 | 130 |
| Operating income | −11 | −47 | −56 | −115 | −170 | −211 | 68 |
| Net income | −12 | −45 | −59 | −105 | −153 | −187 | 87 |
| Diluted EPS (US$) | −6.08 | −2.93 | −2.52 | −4.15 | −5.20 | −5.00 | 2.30 |
| Diluted shares (millions) | 2 | 16 | 23 | 25 | 29 | 37 | 38 |
| Cash flow | |||||||
| Cash from operations | −16 | −37 | −62 | −70 | −124 | −161 | 108 |
| Capital expenditure | 0 | 0 | 1 | 1 | 2 | 2 | 2 |
| Free cash flow | −16 | −37 | −63 | −71 | −127 | −163 | 106 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 375 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 4 | 12 | 19 | 29 | 35 | 29 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 7 | 266 | 230 | 279 | 331 | 560 | 287 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 11 | 269 | 255 | 307 | 370 | 616 | 338 |
| Total liabilities | 10 | 8 | 12 | 29 | 38 | 44 | 35 |
| Shareholders' equity | −19 | 262 | 243 | 277 | 332 | 572 | 303 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −105.6% | — | −280.5% | — | −112,543.7% | — | 27.7% |
| Net margin | −123.4% | — | −292.3% | — | −101,319.2% | — | 35.7% |
| Free cash flow margin | −162.7% | — | −314.3% | — | −84,087.4% | — | 43.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −37.5% | −23.3% | −40.2% | −50.2% | −41.5% | 19.9% |
| Return on assets | — | −32.4% | −22.4% | −37.2% | −45.2% | −38.0% | 18.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |